ALCOX Stock Chart & Stats
€0.43
>-€0.01(-1.83%)
At close: 4:00 PM EST
€0.43
>-€0.01(-1.83%)
Day’s Range― - ―
52-Week Range€0.22 - €0.65
Previous CloseN/A
Volume114.32K
Average Volume (3M)588.51K
Market Cap
€35.53M
Enterprise Value€25.87M
Total Cash (Recent Filing)€11.26M
Total Debt (Recent Filing)€25.79M
Price to Earnings (P/E)―
Beta1.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding93,455,500
10 Day Avg. Volume452,436
30 Day Avg. Volume588,508
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)4.11
Price to Sales (P/S)1.78
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside132.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementAll secured debt was repaid and new unsecured bond financing extended the cash runway, reducing near‑term funding pressure for ongoing development activities.
Clinical Trial ResultsNCX 470 met the primary efficacy endpoint in a second large Phase 3 glaucoma trial and demonstrated faster onset plus stronger pressure‑lowering effect than standard treatments, supporting approval prospects and potential clinician adoption.
Partner Funding And Milestone UpsidePartner Kowa is financing late‑stage development, leading regulatory efforts, and has triggered a milestone payment, leaving Nicox eligible for further submission and sales milestones as well as royalties on net sales.
Bears Say
Commercial Competition RiskAnalyst warns that even if approved, NCX 470 could face limited commercial uptake because the glaucoma market is competitive and gaining market share may be challenging.
Regulatory Approval RiskAnalyst highlights the risk that regulatory approval may not be granted despite positive data, which would materially damage the product’s commercial prospects.
Shareholder Dilution RiskAnalyst cautions that future financing needs could result in shareholder dilution if additional capital is required to complete development or support commercialization.
Nicox SA News
ALCOX FAQ
What was Nicox SA’s price range in the past 12 months?
Nicox SA lowest stock price was €0.22 and its highest was €0.65 in the past 12 months.
What is Nicox SA’s market cap?
Nicox SA’s market cap is €35.53M.
When is Nicox SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nicox SA’s earnings last quarter?
Currently, no data Available
Is Nicox SA overvalued?
According to Wall Street analysts Nicox SA’s price is currently Undervalued.
Does Nicox SA pay dividends?
Nicox SA does not currently pay dividends.
What is Nicox SA’s EPS estimate?
Nicox SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nicox SA have?
Nicox SA has 93,455,500 shares outstanding.
What happened to Nicox SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nicox SA?
Currently, no hedge funds are holding shares in FR:ALCOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nicox SA
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.
ALCOX Stock 12 Month Forecast
Average Price Target
€1.00
▲(132.56% Upside)